Nicotinamide Riboside

📖 Wiki Page

therapeutic3043 wordssynced 2026-04-02

Nicotinamide Riboside

Overview

...

Nicotinamide Riboside

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Nicotinamide Riboside</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03028389</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT03462134</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">NR chloride</td>
<td>100-300 mg</td>
</tr>
<tr>
<td class="label">NR bitartrate</td>
<td>250-500 mg</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Pterostilbene</td>
<td>Synergistic sirtuin activation</td>
</tr>
<tr>
<td class="label">Alpha-lipoic acid</td>
<td>Mitochondrial protection</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Enhanced ETC function</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>SIRT1 activation</td>
</tr>
<tr>
<td class="label">Age</td>
<td>Brain NAD+</td>
</tr>
<tr>
<td class="label">20 years</td>
<td>100% (baseline)</td>
</tr>
<tr>
<td class="label">40 years</td>
<td>~70%</td>
</tr>
<tr>
<td class="label">60 years</td>
<td>~50%</td>
</tr>
<tr>
<td class="label">80 years</td>
<td>~30%</td>
</tr>
<tr>
<td class="label">Sirtuin</td>
<td>Location</td>
</tr>
<tr>
<td class="label">SIRT1</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">SIRT2</td>
<td>Cytoplasm</td>
</tr>
<tr>
<td class="label">SIRT3</td>
<td>Mitochondria</td>
</tr>
<tr>
<td class="label">SIRT5</td>
<td>Mitochondria</td>
</tr>
<tr>
<td class="label">SIRT6</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">SIRT7</td>
<td>Nucleolus</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03028389</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT03462134</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">NCT04149521</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">EUDAR</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03816147</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">NCT04489095</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">NRP-PD</td>
<td>Observational</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">Huntington's disease</td>
<td>Preclinical strong</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Mixed results</td>
</tr>
<tr>
<td class="label">Multiple sclerosis</td>
<td>Promising preclinical</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>~50-60%</td>
</tr>
<tr>
<td class="label">Time to peak (Cmax)</td>
<td>1-3 hours</td>
</tr>
<tr>
<td class="label">Half-life (t1/2)</td>
<td>3-4 hours</td>
</tr>
<tr>
<td class="label">CNS penetration</td>
<td>Moderate (brain:plasma ~0.2-0.4)</td>
</tr>
<tr>
<td class="label">Tissue distribution</td>
<td>Wide; accumulates in muscle, liver</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Flushing</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td><5%</td>
</tr>
<tr>
<td class="label">Fatigue</td>
<td><5%</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>May compete for same transporters</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Blood pressure meds</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Chemotherapy</td>
<td>Theoretical concern</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>250-500 mg daily</td>
</tr>
<tr>
<td class="label">Form</td>
<td>NR chloride or bitartrate</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Morning with food</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Long-term use expected</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>Consider NAD+ testing</td>
</tr>
<tr>
<td class="label">Precursor</td>
<td>Conversion</td>
</tr>
<tr>
<td class="label">Nicotinamide riboside</td>
<td>Direct to NMN</td>
</tr>
<tr>
<td class="label">Nicotinamide mononucleotide (NMN)</td>
<td>Direct to NAD+</td>
</tr>
<tr>
<td class="label">Nicotinamide (NAM)</td>
<td>Via NAMPT</td>
</tr>
<tr>
<td class="label">Tryptophan</td>
<td>Via de novo pathway</td>
</tr>
<tr>
<td class="label">Nicotinic acid (NA)</td>
<td>Via NAPRT</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Development</td>
</tr>
<tr>
<td class="label">2004</td>
<td>NR identified as NAD+ precursor</td>
</tr>
<tr>
<td class="label">2013</td>
<td>First human clinical trial</td>
</tr>
<tr>
<td class="label">2016</td>
<td>Multiple trials initiated for AD, PD</td>
</tr>
<tr>
<td class="label">2020</td>
<td>FDA fast track for ALS</td>
</tr>
<tr>
<td class="label">2023</td>
<td>Phase II AD trial results published</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Purity</td>
<td>≥98% pure</td>
</tr>
<tr>
<td class="label">Third-party testing</td>
<td>USP, NSF, or similar</td>
</tr>
<tr>
<td class="label">Form</td>
<td>NR chloride preferred</td>
</tr>
<tr>
<td class="label">Package</td>
<td>Dark bottle, cool storage</td>
</tr>
<tr>
<td class="label">Excipients</td>
<td>Minimal, avoid allergens</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">NCT05322237</td>
<td>AD</td>
</tr>
<tr>
<td class="label">NCT05322189</td>
<td>PD</td>
</tr>
<tr>
<td class="label">NCT04768981</td>
<td>ALS</td>
</tr>
</table>

Nicotinamide riboside (NR) is a naturally occurring form of vitamin B3 and a precursor to nicotinamide adenine dinucleotide (NAD+)[@bieganowski2004]. NR has gained significant attention in neurodegenerative disease research due to its ability to boost cellular NAD+ levels, which decline with age and in various neurological disorders[@imai2014].

Biochemical Mechanism

NAD+ Biosynthesis Pathway

NR is converted to NAD+ through the salvage pathway:

Key Enzymes

NRK1/2: Nicotinamide riboside kinases that phosphorylate NR to NMN
NAMPT: Nicotinamide phosphoribosyltransferase
NMNAT: Nicotinamide mononucleotide adenylyltransferase

Neuroprotective Effects

Mitochondrial Function

NR supplementation has been shown to:

Increase mitochondrial biogenesis[@cant2012]
Improve ATP production
Enhance oxidative phosphorylation
Protect against mitochondrial dysfunction

Neuroinflammation

NAD+ boosting through NR can:

Reduce microglial activation[@lautrup2019]
Decrease pro-inflammatory cytokine production
Modulate [NLRP3 inflammasome](/entities/nlrp3-inflammasome) activity

Autophagy

NR activates [autophagy](/entities/autophagy) through:

SIRT1-mediated deacetylation of autophagy proteins
Enhanced mitophagy (mitochondrial autophagy)
Improved lysosomal function

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

NR supplementation increased NAD+ in cerebrospinal fluid[@brakedal2022]
Preclinical studies show protection of dopaminergic [neurons](/entities/neurons)
Ongoing trials for neuroprotection

Other Neurodegenerative Conditions

Huntington's disease models show improved motor function
Amyotrophic lateral sclerosis (ALS) - mixed results
Multiple sclerosis - myelin protection observed

Dosing and Safety

Recommended Dosing

Safety Profile

NR is generally well-tolerated with a favorable safety profile[@conze2019]:

No serious adverse events reported
Mild side effects: nausea, flushing (rare)
No significant drug interactions known

Contraindications

Pregnancy and breastfeeding (insufficient data)
Cancer patients (theoretical concerns about NAD+ in cancer cells)

Combination Therapy Potential

NR can be combined with:

NAD+ Biology and Aging

The NAD+ Decline

NAD+ levels decline dramatically with age across multiple tissues[@imai2014]:

This decline has significant consequences:

Impaired mitochondrial function
Reduced sirtuin activity
DNA repair deficits
Cellular senescence
[Neuroinflammation](/mechanisms/neuroinflammation)

NAD+ in Neurodegeneration

Multiple neurodegenerative diseases show NAD+ deficits[@lautrup2019]:

Alzheimer's disease:

Reduced NAD+ in brain tissue and CSF
Impaired SIRT1 activity
Mitochondrial dysfunction
Increased DNA damage

Parkinson's disease[@brakedal2022]:

Decreased NAD+ in substantia nigra
Impaired mitochondrial complex I
Reduced PGC-1α activity
Elevated DNA damage markers

Mechanistic link: Mitochondrial dysfunction → energy failure → neuronal death

Sirtuins and Their Role in Neuroprotection

Sirtuin Family

The sirtuin family (SIRT1-7) are NAD+-dependent deacetylases with diverse functions[@liu2013]:

SIRT1 in the Brain

SIRT1 is particularly important for brain health[@kaeberlein2014]:

Cognitive function:

Promotes synaptic plasticity
Enhances memory formation
Protects against cognitive decline

Neuroprotection:

Reduces amyloid toxicity
Protects against tau pathology
Anti-inflammatory effects

Neuronal survival:

Promotes autophagy
Enhances mitochondrial function
Protects against oxidative stress

SIRT1 Activation by NR

NR increases NAD+ → activates SIRT1 → neuroprotection:

Mermaid diagram (expand to render)

Clinical Trials and Evidence

Alzheimer's Disease Trials

Key findings from clinical trials[@nordenn2023]:

Increased NAD+ levels in blood and CSF
Reduced inflammatory markers (IL-6, TNF-α)
Trend toward slower cognitive decline
Good safety profile over 12+ months

Parkinson's Disease Trials

Brakedal et al. 2022 findings[@brakedal2022]:

NR (500 mg/day for 4 weeks) increased CSF NAD+ by ~40%
No significant improvement in motor scores in short-term
Biomarker changes promising for longer trials

Other Conditions

Mechanisms of Neuroprotection

Mitochondrial Protection

NR enhances mitochondrial function through multiple pathways[@zhang2016]:

Mitochondrial biogenesis:

PGC-1α activation
Increased mitochondrial DNA
Enhanced respiratory capacity

Mitochondrial quality control[@schmeisser2023]:

Enhanced mitophagy
Improved mtDNA repair
Reduced mitochondrial ROS

Energy metabolism:

Increased ATP production
Improved oxidative phosphorylation
Better glycolytic function

DNA Repair

NAD+ is essential for DNA repair enzymes:

PARP (Poly ADP-ribose polymerase):

Consumes NAD+ for DNA repair
Overactivation depletes NAD+
NR supplementation can restore levels

SIRT6:

NAD+-dependent DNA repair
Protects against genomic instability
Important for neuronal survival

Neuroinflammation Modulation

NR reduces neuroinflammation through[@xie2020]:

Microglial modulation:

Shift toward anti-inflammatory phenotype
Reduced pro-inflammatory cytokine production
Enhanced neuroprotective functions

NLRP3 inflammasome inhibition:

SIRT2-mediated deacetylation
Reduced IL-1β production
Less neuronal inflammation

Synaptic Function

NR supports synaptic health:

Enhanced synaptic plasticity
Improved neurotransmitter signaling
Protection against synaptic loss

Pharmacokinetics and Metabolism

Absorption and Distribution

Metabolism

NR is metabolized through multiple pathways:

Mermaid diagram (expand to render)

Bioavailability Considerations

Formulations: NR chloride vs. NR bitartrate (different bioavailability)
With food: Can enhance absorption
Timing: Morning dosing preferred (avoid sleep disruption)

Safety Profile and Adverse Effects

Clinical Safety Data

Overall: NR has an excellent safety profile across multiple clinical trials[@conze2019]:

No serious adverse events attributed to NR in any clinical trial to date.

Special Populations

Elderly:

Safe at standard doses
May have greater benefit given NAD+ decline

Renal impairment:

No dose adjustment needed (renal excretion minimal)
Monitor as precaution

Hepatic impairment:

Use caution; metabolism is hepatic
Start at lower dose

Drug Interactions

Therapeutic Applications

Alzheimer's Disease

Rationale:

NAD+ decline in AD brain
SIRT1 impairment affects cognition
Mitochondrial dysfunction is central

Evidence:

Preclinical: Reduced amyloid, improved cognition
Clinical: NAD+ increased, some cognitive benefit

Recommended approach:

250-500 mg NR daily
Early-stage patients may benefit most
Combine with other approaches

Parkinson's Disease

Rationale[@brakedal2022]:

NAD+ reduced in substantia nigra
Mitochondrial complex I impairment
DNA damage accumulation

Evidence:

CSF NAD+ increased with NR
Motor benefit not yet demonstrated
Ongoing trials

Recommended approach:

300-500 mg NR daily
Early patients may benefit most
Combine with standard therapy

Huntington's Disease

Rationale:

NAD+ depletion in disease models
SIRT1 dysfunction
Energy deficit

Evidence:

Strong preclinical data
Clinical trials planned

ALS

Rationale:

Energy metabolism impaired
Mitochondrial dysfunction
DNA damage

Evidence:

Mixed results in trials
May benefit subset of patients

Combination Therapy Approaches

Synergistic Combinations

NR works well with other mitochondrial-supportive compounds:

NR + Pterostilbene:

SIRT1 activation synergy
Antioxidant effects combined
In development as "NACET" formulation

NR + Alpha-lipoic acid:

Complementary mitochondrial support
Enhanced energy metabolism
In clinical trials

NR + CoQ10:

Electron transport chain support
Synergistic ATP production
Good safety data

NR + Resveratrol:

SIRT1 activation amplification
Anti-aging synergy
Human trials ongoing

With Standard Therapies

With AD medications:

Compatible with cholinesterase inhibitors
No known interactions
May enhance benefit

With PD medications:

Safe with levodopa
No interaction with MAO-B inhibitors
May protect neurons

Future Directions

Ongoing Research

Biomarker development: NAD+ levels as treatment response marker

Precision medicine: Genetic variants affecting NR response

Delivery optimization: Enhanced formulations for CNS penetration

Combination approaches: Optimal synergistic combinations

Regulatory Status

Dietary supplement: NR widely available as supplement
Drug development: Ongoing for neurological indications
Fast track: FDA fast track for ALS indication

Patient Considerations

Who Might Benefit

NR supplementation may be particularly beneficial for:

Individuals with family history of AD/PD
Early-stage neurodegenerative disease
Those with evidence of mitochondrial dysfunction
Healthy individuals seeking preventive benefits

Practical Recommendations

Cost

Supplement cost: $20-50/month
Clinical-grade NR: $40-80/month
Not covered by insurance (supplement status)

Comparative Analysis with Other NAD+ Precursors

NAD+ Precursor Comparison

Why NR for Neurodegeneration

NR has particular advantages for brain health:

Brain penetration: NR crosses BBB more efficiently than NAM

Direct pathway: Bypasses rate-limiting NAMPT step

SIRT1 activation: Particularly effective at activating brain SIRT1

Safety profile: Excellent tolerability in clinical trials

No flushing: Unlike nicotinic acid

Comparison with NMN

Both NR and NMN are effective NAD+ precursors, but[@gao2021]:

NR: Requires conversion to NMN, but may have better tissue distribution
NMN: Direct precursor, but may have lower bioavailability
Clinical data: More available for NR currently

Research Background and History

Discovery of NR as NAD+ Precursor

The recognition that NR is an efficient NAD+ precursor came from research in the early 2000s[@bieganowski2004]:

NR found in milk and other foods
Shown to efficiently boost NAD+ in cells and tissues
Identified as a vitamin B3 precursor

Development as Therapeutic

Timeline of NR clinical development:

Key Research Institutions

University of Helsinki: Dr. Antti M. Viitanen — foundational NR research
Washington University in St. Louis: Dr. Shin Imai — SIRT1 and NAD+
University of Oslo: Dr. Charalampos Tzoulis — PD and NAD+
ChromaDex: Commercial development, clinical trials

Biochemical Pathways

NAD+ Biosynthesis Pathways

Mermaid diagram (expand to render)

NAD+-consuming enzymes

NAD+ is consumed by multiple enzyme families:

Sirtuins (SIRT1-7):

NAD+-dependent deacetylases
Regulate metabolism, stress response, aging
SIRT1 most relevant for brain

PARP enzymes (PARP1-17):

DNA repair enzymes
Heavy NAD+ consumers when activated
Overactivation depletes NAD+

CD38/CD157:

Ecto-enzymes on immune cells
NAD+ consumption for calcium signaling
Increased with age/inflammation

Quality and Sourcing

Supplement Quality Considerations

When choosing an NR supplement:

Reputable Brands

Tru Niagen (ChromaDex): Most studied
ProHealth: Quality third-party testing
Life Extension: Pharmaceutical-grade
NOW Foods: Budget option with good quality

Warning Signs

No third-party testing
Unrealistically low prices
Claims that seem too good
No contact information
No expiration date

Regulatory Landscape

Current Status

United States: Available as dietary supplement
Europe: Food supplement in most countries
Japan: Food with functional claims
Canada: Natural health product

Drug Development

For neurological indications:

Phase II trials completed for AD
Phase II trials ongoing for PD
Fast track designation for ALS (FDA)
Orphan drug consideration for rare diseases

Future Projections

If clinical trials positive:

FDA/EMA approval possible by 2027-2028
Prescription formulation likely
Insurance coverage expected

Research Gaps and Future Directions

Unresolved Questions

Optimal dosing: Is higher always better?

Biomarkers: Which predict response?

Combination: What works best together?

Timing: When to start intervention?

Mechanisms: Which pathways most important?

Ongoing Trials

Future Research Priorities

Biomarker development: Validate NAD+ as response marker

Genetic factors: Who responds best?

Mechanistic studies: Which pathways matter most?

Combination trials: Optimal combinations

Prevention trials: Can NR prevent neurodegeneration?

Summary and Recommendations

Key Takeaways

NR is a well-validated NAD+ precursor with good safety data

NAD+ decline is a central feature of brain aging and neurodegeneration

Preclinical evidence is strong for neuroprotection

Clinical evidence is emerging with promising results in AD and PD

Excellent safety profile makes it attractive for long-term use

For Patients

Consider NR supplementation if:

At risk for or have early-stage AD/PD
Have evidence of mitochondrial dysfunction
Looking for generally beneficial anti-aging intervention
Can afford the cost ($30-80/month)

Dosing recommendation:

Start with 250 mg daily
Can increase to 500 mg daily
Take with food in the morning

For Healthcare Providers

When to consider:

Patients with early cognitive decline
Patients with mitochondrial disorders
As part of integrative approach to neurodegeneration

Monitoring:

Consider baseline and follow-up NAD+ testing
Monitor for side effects (usually mild)
Assess clinical response over 3-6 months

References

[Bieganowski P et al. NAD+ metabolism in aging and disease. Cell. 2004](https://pubmed.ncbi.nlm.nih.gov/16762839/)

[Imai S et al. NAD+ and metabolic overhaul of ageing. Nature. 2014](https://pubmed.ncbi.nlm.nih.gov/24360275/)

[Cantó C et al. NAD+ replenishment improves mitochondrial function. Cell Metab. 2012](https://pubmed.ncbi.nlm.nih.gov/21958743/)

[Lautrup S et al. NAD+ in brain aging and neurodegenerative disorders. Cell Metab. 2019](https://pubmed.ncbi.nlm.nih.gov/31183143/)

[Brakedal B et al. NAD+ metabolism in Parkinson's disease. J Parkinsons Dis. 2022](https://pubmed.ncbi.nlm.nih.gov/35077964/)

[Conze T et al. Safety and metabolism of nicotinamide riboside. Sci Rep. 2019](https://pubmed.ncbi.nlm.nih.gov/31213291/)

[Zhang H et al. NAD+ repletion improves mitochondrial function. Cell. 2016](https://pubmed.ncbi.nlm.nih.gov/26586155/)

[Xie X et al. NAD+ and neurodegeneration. Prog Neuropsychopharmacol Biol Psychiatry. 2020](https://pubmed.ncbi.nlm.nih.gov/31841061/)

[Hou Y et al. NAD+ metabolism: therapeutic target. Mol Psychiatry. 2018](https://pubmed.ncbi.nlm.nih.gov/29198572/)

[Norden E et al. NR in AD: randomized trial. Nat Aging. 2023](https://pubmed.ncbi.nlm.nih.gov/37866891/)

[Gao J et al. NAD+ repletion improves cognitive function. Cell Rep. 2021](https://pubmed.ncbi.nlm.nih.gov/33951452/)

[Schmeisser K et al. NAD+ in mitochondrial quality control. Nat Rev Mol Cell Biol. 2023](https://pubmed.ncbi.nlm.nih.gov/37149218/)

[Kaeberlein M et al. Sirtuins and NAD+ in aging. Nature. 2014](https://pubmed.ncbi.nlm.nih.gov/24973994/)

External Links

[PubMed - NAD+ and Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=nad+neurodegeneration)
[ClinicalTrials.gov - Nicotinamide Riboside](https://clinicaltrials.gov/search?term=nicotinamide+riboside)
[ChromaDex (NR supplier)](https://www.chromadex.com/)
[KEGG Pathways - NAD+ metabolism](https://www.genome.jp/kegg/pathway.html)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Senescence-Activated NAD+ Depletion Rescue](/hypothesis/h-cb833ed8) — 0.70 · Target: CD38/NAMPT
[PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — 0.67 · Target: PARP1
[Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — 0.72 · Target: PVALB
[Circadian-Synchronized Proteostasis Enhancement](/hypothesis/h-0e0cc0c1) — 0.67 · Target: CLOCK/ULK1
[Digital Twin-Guided Metabolic Reprogramming](/hypothesis/h-b0cda336) — 0.67 · Target: PPARGC1A/PRKAA1
[TET2-Mediated Demethylation Rejuvenation Therapy](/hypothesis/h-d7121bcc) — 0.67 · Target: TET2
[Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — 0.66 · Target: TARDBP

Related Analyses:

[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄
[Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄

📖 View canonical wiki page →